TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23933108
Drug: Integrated Behavior
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated Behavior Therapy for Selective Mutism (IBTSM)
Study: 20462395
Drug: Topical amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical amphotericin B (0.2 mg/mL) eye drops every 2 hours for 21 days and subconjunctival fluconazole (2 mg/mL) injections
Study: 18405818
Drug: Extraction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraction therapy (removal of 4 premolars)
Study: 18405818
Drug: Nonextraction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonextraction therapy with air-rotor stripping (ARS)
Study: 14633755
Drug: Nefopam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (20 mg every 4 h for 24 h)
Study: 10724301
Drug: Salbutamol delivered
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol delivered via conventional pressurized metered-dose inhaler (MDI)
Study: 6385444
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg trimethoprim
Study: 30712923
Drug: Spironolactone 50
Normalized name: spironolactone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 50 mg once daily
Study: 30806492
Drug: Acceptance-Based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-Based Treatment (ABT)
Study: 20824976
Drug: Soybean oil
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil supplementation (20 mL daily) during late pregnancy and first six months of lactation
Study: 18821156
Drug: Allopurinol (XO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (XO inhibitor)
Study: 9642600
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (Group 1) with bupivacaine 0.75% and intravenous midazolam and fentanyl.
Study: 9642600
Drug: Retrobulbar anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar anesthesia (Group 2) with intravenous methohexital followed by retrobulbar block with an equal mixture of lidocaine 2% and bupivacaine 0.75% plus hyaluronidase 150 units.
Study: 9642600
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia (Group 1)
Study: 7506007
Drug: Serum potassium
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum potassium < 3.5 mmol/L
Study: 351600
Drug: Fludilat (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludilat (3 tablets per day for 3 months)
Study: 29916929
Drug: Topical TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TXA (3 g diluted in 45 mL normal saline, applied after cementation)
Study: 29916929
Drug: IV TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV TXA (1 g prior to tourniquet inflation and 1 g at closure)
Study: 17258423
Drug: Hydroxyzine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 1.5 mg/kg
Study: 3301980
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir (200 mg), administered five times per day for 5 days
Study: 28857425
Drug: MCP (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCP (30 billion CFUs per sachet, 2 sachets daily for 4 weeks) and omega-3 fatty acid (2 g daily for 8 weeks)
Study: 24767875
Drug: Aspirin (624
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (624 mg once daily for 6 months)
Study: 24767875
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily for 6 months)
Study: 19773525
Drug: Teduglutide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teduglutide (2.5 to 80 mg, daily subcutaneous administration)
Study: 12881377
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of mammography and physical examination
Study: 8826153
Drug: Biofeedback treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback treatment (10 weekly sessions of 15 minutes' duration)
Study: 3582466
Drug: Enprofylline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline (1 mg/kg body weight over 10 min) with terbutaline pretreatment (4 micrograms/kg body weight)
Study: 3582466
Drug: Enprofylline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline (1 mg/kg body weight over 10 min) with placebo pretreatment
Study: 30289578
Drug: Tablet-based application
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based application (eMedHAT)
Study: 28858247
Drug: Probiotic (10⁸
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (10⁸ CFUs of L. reuteri DSM 17938)
Study: 20718754
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (granisetron and dexamethasone)
Study: 17716750
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (40 children)
Study: 15817818
Drug: Clopidogrel (300‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300‐mg loading dose and 75‐mg maintenance dose)
Study: 9882033
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg o.m. pantoprazole
Study: 9882033
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg o.m. pantoprazole
Study: 9882033
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg b.d. pantoprazole
Study: 2898901
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug (control group IV)
Study: 28739782
Drug: PZA (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZA (10 or 25 mg/kg) plus allopurinol (100 mg daily)
Study: 20450369
Drug: AMSA injection
Normalized name: m-AMSA
DrugBank: Amsacrine (DB00276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMSA injection
Study: 9401313
Drug: Augmentation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation therapy with triiodothyronine (T3)
Study: 9401313
Drug: Substitution therapy
Normalized name: hydroxypropyl cellulose, low substituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substitution therapy (replacing one antidepressant with another)
Study: 9401313
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (adding a second antidepressant to the first)
Study: 3900456
Drug: TMS-19-Q.GC tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMS-19-Q.GC tablet (TMS)
Study: 3900457
Drug: Josamycin tablet
Normalized name: josamycin
DrugBank: Josamycin (DB01321)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Josamycin tablet (JM)
Study: 27509600
Drug: Acupuncture method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture method of 'Xingnao Kaiqiao' and oral administration of nifedipine (Control group)
Study: 22669570
Drug: Ridaforolimus 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridaforolimus 40 mg in fasted state
Study: 22669570
Drug: Ridaforolimus 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridaforolimus 40 mg with light breakfast
Study: 22669570
Drug: Ridaforolimus 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridaforolimus 40 mg with high-fat breakfast
Study: 16274475
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri (108 Colony Forming Units daily for 80 days)
Study: 6461999
Drug: d‐tubocurarine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐tubocurarine (0.05 mg/kg)
Study: 6461999
Drug: alcuronium (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: alcuronium (0.03 mg/kg)
Study: 6461999
Drug: pancuronium (0.008
Approvals — FDA: no, EMA: no, PMDA: no
Description: pancuronium (0.008 mg/kg)
Study: 23769246
Drug: Ketorolac 1
Normalized name: ketorolac 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 1 mg/kg
Study: 23769246
Drug: Ketoprofen 50
Normalized name: ketoprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 50 mg + 50 mg tramadol
Study: 23769246
Drug: Ketoprofen 100
Normalized name: ketoprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 100 mg + 100 mg tramadol
Study: 21208398
Drug: Anthelmintic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthelmintic treatment programme (oral ivermectin and fenbendazole)
Study: 16718798
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL epinephrine
Study: 16718798
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL epinephrine
Study: 16718798
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL epinephrine
Study: 11513170
Drug: Eradication treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication treatment (lansoprazole 15 mg b.i.d., amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d.)
Study: 11513170
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (lansoprazole 15 mg b.i.d. and placebo)
Study: 9278202
Drug: Study group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study group received counseling about their medicines and a pharmaceutical care plan.
Study: 9278202
Drug: Study group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study group had unintentional changes to medication found during the visit.
Study: 9278202
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group had unintentional changes to medication found during the visit.
Study: 8305360
Drug: alpha IFN-2b
Normalized name: RAD-IFN-2B
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha IFN-2b maintenance therapy post-DHBI
Study: 3524665
Drug: Oral oestradiol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestradiol, 2 mg daily plus oestriol, 1 mg daily
Study: 3524665
Drug: Oral oestradiol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestradiol, 2 mg daily
Study: 30916364
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 1g/kg flaxseeds and 1g/kg fenugreek seeds
Study: 23080086
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue spray applied to the axillary fossa in 40 patients
Study: 23080086
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment in 40 patients
Study: 2095345
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg alone (F)
Study: 2095345
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg and Triamterene 50 mg (F + T)
Study: 2095345
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of Furosemide 40 mg and Triamterene 50 mg (FT)
Study: 30452776
Drug: CSL112 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 2 g (n = 6)
Study: 30452776
Drug: CSL112 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 6 g (n = 6)
Study: 30452776
Drug: CSL112 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 (both doses)
Study: 28457194
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ICG administered 3 to 7 hours before imaging
Study: 28457194
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ICG administered 5 to 25 hours before imaging
Study: 28457194
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ICG administered up to 3 hours before imaging
Study: 28457194
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ICG administered up to 5 hours before imaging
Study: 10498560
Drug: Penicillin G
Normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin G benzathine
Study: 2191993
Drug: L-648,051 (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-648,051 (inhaled cysteinyl leukotriene antagonist)
Study: 6782930
Drug: Lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicylate (LAS) 125 mg/10 kg
Study: 6782930
Drug: Lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicylate (LAS) 250 mg/10 kg
Study: 6782930
Drug: Oxycodone 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.4 mg/10 kg
Study: 6782930
Drug: Oxycodone 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.8 mg/10 kg
Study: 6782930
Drug: Lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicylate (LAS) 250 mg/10 kg and Oxycodone 0.8 mg/10 kg
Study: 31198138
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula oxygen therapy (HFNC) with initial flow rate of 40 L/min
Study: 28348504
Drug: Dexamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2 ml, 8 mg) with bupivacaine (18 ml, 0.5%)
Study: 28348504
Drug: Control (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2 ml normal saline with bupivacaine (18 ml, 0.5%))
Study: 24642392
Drug: Biological antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological antioxidant potential (BAP) levels measured at 6 months
Study: 21502546
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) alone, consisting of goserelin and bicalutamide for 2 years
Study: 15857212
Drug: D-002 40
Normalized name: D
DrugBank: Rosomidnar (DB17154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-002 40 mg/day
Study: 15857212
Drug: D-002 100
Normalized name: D
DrugBank: Rosomidnar (DB17154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-002 100 mg/day
Study: 10643535
Drug: Chemoendocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoendocrine therapy with mitozantrone and methotrexate (2M) +/‐ mitomycin‐C (3M) and tamoxifen, used concurrently with radiation
Study: 27866873
Drug: Open-label tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Open-label tenofovir (300 mg daily) for 1 year
Study: 21917824
Drug: SC abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SC abatacept (125 mg)
Study: 21917824
Drug: SC abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SC abatacept (125 mg) reintroduced after placebo
Study: 19444379
Drug: Beverage containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beverage containing 200 mg calcium and 5 microg vitamin D daily for 30 days
Study: 19444379
Drug: Beverage containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beverage containing 200 mg calcium daily for 30 days
Study: 30477276
Drug: Lowest serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest serum 25(OH)D quartile (4.7–17.5 ng/mL)
Study: 22197127
Drug: degarelix-ML group
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: degarelix-ML group
Study: 9935007
Drug: No antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiarrhythmic medication (ICD-only group)
Study: 7591508
Drug: Subjects with
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects with higher absorption and sustained attention
Study: 2267970
Drug: Ivermectin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (150 micrograms/kg) administered monthly for 12 months
Study: 2267970
Drug: Ivermectin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (150 micrograms/kg) administered monthly for 8 and 12 months
Study: 2267970
Drug: Ivermectin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (150 micrograms/kg) administered monthly
Study: 6104874
Drug: Fixed betablocker
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed betablocker diuretic combination (Torrat, Boehringer Mannheim GmbH)
Study: 31798894
Drug: Boot Camp
Normalized name: Booty Goo
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Boot Camp intervention (diabetes education and medication management via initial clinic and weekly virtual visits for 90 days)
Study: 27590218
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg per day (reduced to 30 mg if certain factors present)
Study: 24604308
Drug: Doxycycline 50
Normalized name: doxycycline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 50 mg daily for 24 months
Study: 22313516
Drug: Amantadine 50
Normalized name: amantadine 50 mg/5 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine 50 or 100 mg
Study: 21742102
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of isosorbide dinitrate/hydralazine (FDC I/H)
Study: 12374520
Drug: Glucosamine sulfate,
Normalized name: Glucosamine Sulfate, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine sulfate, 1500 mg once a day
Study: 10815855
Drug: Excimer laser‐generated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excimer laser‐generated 308‐nm UV‐B radiation (1 treatment at 8 and 16 MED multiples)
Study: 8984537
Drug: Sequential empiric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential empiric therapy including amikacin and amphotericin B
Study: 29448265
Drug: Mini dental
Normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini dental implants (MDI)
Study: 29448265
Drug: Standard-size implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-size implants (SSI)
Study: 24570078
Drug: Nicardipine continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine continuous infusion (0.5 µg/kg per min)
Study: 20357309
Drug: Computerised cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerised cognitive-behavioural therapy (CCBT)
Study: 18418966
Drug: Tongguan Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongguan Capsule (TGC)
Study: 18418966
Drug: Western routine
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western routine therapy with anti-thrombosis and anti-coagulant agents
Study: 16186280
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg vitamin C and 100 IU vitamin E (group V)
Study: 16186280
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of magnesium plus zinc, vitamins C plus E (group MV)
Study: 16186280
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Mg and 30 mg Zn (group M)
Study: 12639462
Drug: CCM (cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCM (cell culture medium supplemented with insulin, thyroxin and growth hormone)
Study: 11018196
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg IR
Study: 11018196
Drug: Fluvastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 80 mg ER
Study: 11018196
Drug: Fluvastatin 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 160 mg ER
Study: 11018196
Drug: Fluvastatin ER
Normalized name: fluvastatin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin ER (all doses)
Study: 8639252
Drug: CyA (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA (7 mg/kg per day) and prednisolone
Study: 8639252
Drug: CyA (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA (7 mg/kg per day), prednisolone, and oral nifedipine
Study: 8639252
Drug: CyA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA (4 mg/kg per day), prednisolone, and azathioprine
Study: 29719179
Drug: Verubecestat 12
Normalized name: Verubecestat
DrugBank: Verubecestat (DB12285)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verubecestat 12 mg per day
Study: 29719179
Drug: Verubecestat 40
Normalized name: Verubecestat
DrugBank: Verubecestat (DB12285)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verubecestat 40 mg per day
Study: 28620677
Drug: LEB +
Normalized name: Leuprolide acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEB + peloid therapy (5 days a week for 2 weeks)
Study: 28620677
Drug: LEB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEB treatment alone
Study: 25124939
Drug: Oleogel‐S10 once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleogel‐S10 once daily (n = 53)
Study: 25124939
Drug: Oleogel‐S10 twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleogel‐S10 twice daily (n = 51)
Study: 25124939
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily (n = 25)
Study: 25124939
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily (n = 28)
Study: 17531632
Drug: Gabexate mesylate
Normalized name: mesylate
DrugBank: Gabexate (DB12831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesylate 500 mg administered within 1 hour before ERCP (group A, 203 patients)
Study: 17531632
Drug: Gabexate mesylate
Normalized name: mesylate
DrugBank: Gabexate (DB12831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesylate 500 mg administered within 1 hour after ERCP (group B, 203 patients)
Study: 17531632
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (group C, 202 patients)